Prescription Drug Monitoring Program - Data Disclosure to Federal Law Enforcement - Limitation
Summary
HB1045 updates Maryland’s health insurance, family planning, and medical-record confidentiality laws to conform to current federal references and to expand certain state protections. The bill revises multiple provisions in the Health-General and Insurance articles to replace older federal dates with December 31, 2024, for purposes such as grandfathered plans, summaries of benefits and coverage, medical loss ratios, catastrophic coverage, cost-sharing limits, prescription drug coverage, and rescission standards. It also updates family planning program definitions and funding rules so Maryland can continue to support family planning services if federal Title X funding changes or excludes certain providers.
The bill also broadens the definition of “sensitive health services” and “legally protected health care” to include gender-affirming care for purposes of confidentiality protections around disclosure of medical information. In addition, it gives the Maryland Insurance Commissioner and the Commission on Civil Rights concurrent jurisdiction to enforce certain health-insurance discrimination provisions and authorizes the Commissioner to adopt implementing regulations. The act takes effect June 1, 2025.
Impact
HB1045 amends provisions in the Maryland Code, primarily in the Health – General and Insurance articles, to update state law references to federal health-care standards and to preserve state administration of family planning and insurance consumer-protection programs. It affects the Maryland Medical Assistance Program, the Family Planning Program, and insurance regulatory provisions governing plan standards, coverage disclosures, and anti-discrimination enforcement. The bill also expands confidentiality protections for medical records involving gender-affirming care and clarifies enforcement authority between the Insurance Commissioner and the Commission on Civil Rights.
Sentiment
The available voting history suggests the bill was generally supported, with substantial majorities passing on third reading in both chambers (101-37 in the House and 35-11 in the Senate). No committee transcript excerpts were provided, so there is no recorded committee debate to indicate detailed support or opposition arguments. Overall, the vote pattern indicates broad but not unanimous approval, consistent with a consumer-protection and technical-update bill that also includes more substantive policy changes.
Contention
The main points of potential contention are the bill’s inclusion of gender-affirming care in the definition of sensitive health services and its expansion of confidentiality protections, which may draw ideological disagreement. Another possible area of debate is the family-planning language that allows Maryland to continue funding services if federal Title X rules exclude certain providers, reflecting ongoing disputes over abortion-related and reproductive-health provider eligibility. The insurance enforcement provisions, including shared jurisdiction with the Commission on Civil Rights, may also raise questions about regulatory authority, though the vote margins suggest these issues did not prevent passage.